Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.88 |
| ▸ | PSMB1 | P20618 | 11/20 | 0.76 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.76 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.66 |
| ▸ | PDE1A | P54750 | 2/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.66 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597039 | 0.99 | ESR1 (0.89) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7598249 | 0.93 | ESR1 (1.00) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7598246 | 0.93 | ESR1 (1.00) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL23266951 | 0.91 | PSMB1 (0.87) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7601189 | 0.89 | ESR1 (0.74) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7704152 | 0.89 | ESR1 (0.70) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL23266946 | 0.85 | PSMB1 (0.97) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7650153 | 0.84 | PSMB1 (1.00) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL7650156 | 0.84 | PSMB1 (1.00) | ESR1PSMB1PSMB5PSMB2ESR2 | |
| SCHEMBL30902018 | 0.84 | PSMB1 (1.00) | ESR1PSMB1PSMB5PSMB2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | claimed |
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | ESR1 6/4885PSMB1 1502/4885PSMB5 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.